Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 8/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009129 | 1.00 | KMT2A (0.50) | KMT2ATAAR1HPGDNAMPTTSHR | |
| SCHEMBL14009128 | 0.85 | HDAC3 (0.50) | NAMPT | |
| SCHEMBL14009174 | 0.80 | NAMPT (0.47) | NAMPT | |
| SCHEMBL14009091 | 0.78 | SMYD3 (0.49) | KMT2AHPGDNAMPTTSHRALDH1A1 | |
| SCHEMBL14009095 | 0.78 | SMYD3 (0.49) | KMT2AHPGDNAMPTTSHRMEN1 | |
| SCHEMBL14009108 | 0.78 | SMYD3 (0.53) | HPGDALDH1A1 | |
| SCHEMBL14009119 | 0.77 | SMYD3 (0.48) | KMT2AHPGDTSHRMEN1ALDH1A1 | |
| SCHEMBL14009094 | 0.77 | ROCK1 (0.42) | KMT2ANAMPTALDH1A1POLB | |
| SCHEMBL14009182 | 0.77 | ACKR3 (0.49) | — | |
| SCHEMBL14009084 | 0.77 | NAMPT (0.44) | KMT2ANAMPTMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | KMT2A 806/4885TAAR1 3698/4885HPGD 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.